Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

长链非编码RNA细胞骨架调节剂(CYTOR)寄食于microRNA- 206 (miR-206)促进HP75细胞增殖和侵袭

卷 21, 期 6, 2021

发表于: 02 March, 2021

页: [526 - 535] 页: 10

弟呕挨: 10.2174/1568009621666210302090309

价格: $65

摘要

背景：长链非编码RNA细胞骨架调节剂(CYTOR)在侵袭性垂体腺瘤(IPA)中的作用及机制尚未阐明。 目的：本研究以HP75细胞为模型，研究CYTOR与miR-206的相互作用及其在IPA中的作用 方法：CYTOR在IPA组织和细胞系中上调。CYTOR的高表达与患者的腺瘤浸润性和腺瘤大小有关。CYTOR下调可降低HP75细胞的增殖、迁移和侵袭能力，而miR-206上调可抑制HP75细胞的增殖、迁移和侵袭能力。miR-206是CYTOR的一个靶点，在IPA中可受其负调控。 结果：CYTOR作为促肿瘤因子，通过寄食于miR-206促进HP75细胞的增殖、迁移和侵袭。 结论：CYTOR-miR-206轴为IPA的诊断和治疗提供了新的见解。

关键词: 侵袭性垂体腺瘤，CYTOR

« Previous Next »
图形摘要

[1]
Daly, A.F.; Rixhon, M.; Adam, C.; Dempegioti, A.; Tichomirowa, M.A.; Beckers, A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab., 2006, 91(12), 4769-4775.
[http://dx.doi.org/10.1210/jc.2006-1668] [PMID: 16968795]
[2]
Fernandez, A.; Karavitaki, N.; Wass, J.A. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. (Oxf.), 2010, 72(3), 377-382.
[http://dx.doi.org/10.1111/j.1365-2265.2009.03667.x] [PMID: 19650784]
[3]
Raverot, G.; Jouanneau, E.; Trouillas, J. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. Eur. J. Endocrinol., 2014, 170(4), R121-R132.
[http://dx.doi.org/10.1530/EJE-13-1031] [PMID: 24431196]
[4]
Li, J.; Meng, H.; Bai, Y.; Wang, K. Regulation of lncRNA and its role in cancer metastasis. Oncol. Res., 2016, 23(5), 205-217.
[http://dx.doi.org/10.3727/096504016X14549667334007] [PMID: 27098144]
[5]
Wei, G.H.; Wang, X. lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. Eur. Rev. Med. Pharmacol. Sci., 2017, 21(17), 3850-3856.
[PMID: 28975980]
[6]
She, K.; Huang, J.; Zhou, H.; Huang, T.; Chen, G.; He, J. lncRNA-SNHG7 promotes the proliferation, migration and invasion and inhibits apoptosis of lung cancer cells by enhancing the FAIM2 expression. Oncol. Rep., 2016, 36(5), 2673-2680.
[http://dx.doi.org/10.3892/or.2016.5105] [PMID: 27666964]
[7]
Renganathan, A.; Felley-Bosco, E. Long noncoding RNAs in cancer and therapeutic potential. Adv. Exp. Med. Biol., 2017, 1008, 199-222.
[http://dx.doi.org/10.1007/978-981-10-5203-3_7] [PMID: 28815541]
[8]
Chunharojrith, P.; Nakayama, Y.; Jiang, X.; Kery, R.E.; Ma, J.; De La Hoz Ulloa, C.S.; Zhang, X.; Zhou, Y.; Klibanski, A. Tumor suppression by MEG3 lncRNA in a human pituitary tumor derived cell line. Mol. Cell. Endocrinol., 2015, 416, 27-35.
[http://dx.doi.org/10.1016/j.mce.2015.08.018] [PMID: 26284494]
[9]
Yu, G.; Li, C.; Xie, W.; Wang, Z.; Gao, H.; Cao, L.; Hao, L.; Zhang, Y. Long non-coding RNA C5orf66-AS1 is downregulated in pituitary null cell adenomas and is associated with their invasiveness. Oncol. Rep., 2017, 38(2), 1140-1148.
[http://dx.doi.org/10.3892/or.2017.5739] [PMID: 28656268]
[10]
Wu, Z.R.; Yan, L.; Liu, Y.T.; Cao, L.; Guo, Y.H.; Zhang, Y.; Yao, H.; Cai, L.; Shang, H.B.; Rui, W.W.; Yang, G.; Zhang, X.B.; Tang, H.; Wang, Y.; Huang, J.Y.; Wei, Y.X.; Zhao, W.G.; Su, B.; Wu, Z.B. Inhibition of mTORC1 by lncRNA H19 via disrupting 4E-BP1/Raptor interaction in pituitary tumours. Nat. Commun., 2018, 9(1), 4624.
[http://dx.doi.org/10.1038/s41467-018-06853-3] [PMID: 30397197]
[11]
Fu, D.; Zhang, Y.; Cui, H. Long noncoding RNA CCAT2 is activated by E2F1 and exerts oncogenic properties by interacting with PTTG1 in pituitary adenomas. Am. J. Cancer Res., 2018, 8(2), 245-255.
[PMID: 29511595]
[12]
Yu, M.; Xue, Y.; Zheng, J.; Liu, X.; Yu, H.; Liu, L.; Li, Z.; Liu, Y. Linc00152 promotes malignant progression of glioma stem cells by regulating miR-103a-3p/FEZF1/CDC25A pathway. Mol. Cancer, 2017, 16(1), 110.
[http://dx.doi.org/10.1186/s12943-017-0677-9] [PMID: 28651608]
[13]
Zhang, J.; Li, W. Long noncoding RNA CYTOR sponges miR-195 to modulate proliferation, migration, invasion and radiosensitivity in nonsmall cell lung cancer cells. Biosci. Rep., 2018, 38(6), 38.
[http://dx.doi.org/10.1042/BSR20181599] [PMID: 30487160]
[14]
Bian, Z.; Zhang, J.; Li, M.; Feng, Y.; Yao, S.; Song, M.; Qi, X.; Fei, B.; Yin, Y.; Hua, D.; Huang, Z. Long non-coding RNA LINC00152 promotes cell proliferation, metastasis, and confers 5- FU resistance in colorectal cancer by inhibiting miR-139-5p. Oncogenesis, 2017, 6(11), 395.
[http://dx.doi.org/10.1038/s41389-017-0008-4] [PMID: 29180678]
[15]
Cai, Q.; Wang, Z.; Wang, S.; Weng, M.; Zhou, D.; Li, C.; Wang, J.; Chen, E.; Quan, Z. Long non-coding RNA LINC00152 promotes gallbladder cancer metastasis and epithelial-mesenchymal transition by regulating HIF-1α via miR-138. Open Biol., 2017, 7(1), 7.
[http://dx.doi.org/10.1098/rsob.160247] [PMID: 28077595]
[16]
Deng, X.; Zhao, X.F.; Liang, X.Q.; Chen, R.; Pan, Y.F.; Liang, J. Linc00152 promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma. Biomed. Pharmacother., 2017, 90, 100-108.
[http://dx.doi.org/10.1016/j.biopha.2017.03.031] [PMID: 28343069]
[17]
Wang, Y.; Xu, H.; Si, L.; Li, Q.; Zhu, X.; Yu, T.; Gang, X. MiR-206 inhibits proliferation and migration of prostate cancer cells by targeting CXCL11. Prostate, 2018, 78(7), 479-490.
[http://dx.doi.org/10.1002/pros.23468] [PMID: 29542173]
[18]
Hao, W.; Luo, W.; Bai, M.; Li, J.; Bai, X.; Guo, J.; Wu, J.; Wang, M. MicroRNA-206 inhibited the progression of glioblastoma through BCL-2. J. Mol. Neurosci., 2016, 60(4), 531-538.
[http://dx.doi.org/10.1007/s12031-016-0824-6] [PMID: 27558109]
[19]
Wang, T.; Dong, X.M.; Zhang, F.L.; Zhang, J.R. miR-206 enhances nasopharyngeal carcinoma radiosensitivity by targeting IGF1. Kaohsiung J. Med. Sci., 2017, 33(9), 427-432.
[http://dx.doi.org/10.1016/j.kjms.2017.05.015] [PMID: 28865599]
[20]
Liu, F.; Zhao, X.; Qian, Y.; Zhang, J.; Zhang, Y.; Yin, R. MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway. Biomed. Pharmacother., 2017, 96, 229-237.
[http://dx.doi.org/10.1016/j.biopha.2017.08.145] [PMID: 28987947]
[21]
Kondo, Y.; Shinjo, K.; Katsushima, K. Long non-coding RNAs as an epigenetic regulator in human cancers. Cancer Sci., 2017, 108(10), 1927-1933.
[http://dx.doi.org/10.1111/cas.13342] [PMID: 28776911]
[22]
Marín-Béjar, O.; Mas, A.M.; González, J.; Martinez, D.; Athie, A.; Morales, X.; Galduroz, M.; Raimondi, I.; Grossi, E.; Guo, S.; Rouzaut, A.; Ulitsky, I.; Huarte, M. The human lncRNA LINC-PINT inhibits tumor cell invasion through a highly conserved sequence element. Genome Biol., 2017, 18(1), 202.
[http://dx.doi.org/10.1186/s13059-017-1331-y] [PMID: 29078818]
[23]
Mao, Z.; Li, H.; Du, B.; Cui, K.; Xing, Y.; Zhao, X.; Zai, S. LncRNA DANCR promotes migration and invasion through suppression of lncRNA-LET in gastric cancer cells. Biosci. Rep., 2017, 37(6), 37.
[http://dx.doi.org/10.1042/BSR20171070] [PMID: 28951520]
[24]
Yang, J.; Li, C.; Mudd, A.; Gu, X. LncRNA PVT1 predicts prognosis and regulates tumor growth in prostate cancer. Biosci. Biotechnol. Biochem., 2017, 81(12), 2301-2306.
[http://dx.doi.org/10.1080/09168451.2017.1387048] [PMID: 29050519]
[25]
Fu, X.M.; Guo, W.; Li, N.; Liu, H.Z.; Liu, J.; Qiu, S.Q.; Zhang, Q.; Wang, L.C.; Li, F.; Li, C.L. The expression and function of long noncoding RNA lncRNA-ATB in papillary thyroid cancer. Eur. Rev. Med. Pharmacol. Sci., 2017, 21(14), 3239-3246.
[PMID: 28770959]
[26]
Wang, H.; Wang, G.; Gao, Y.; Zhao, C.; Li, X.; Zhang, F.; Jiang, C.; Wu, B. Lnc-SNHG1 activates the TGFBR2/SMAD3 and RAB11A/Wnt/β-Catenin pathway by sponging MiR-302/372/373/520 in invasive pituitary adenomas. Cell. Physiol. Biochem., 2018, 48(3), 1291-1303.
[http://dx.doi.org/10.1159/000492089] [PMID: 30048990]
[27]
Li, Z.; Li, C.; Liu, C.; Yu, S.; Zhang, Y. Expression of the long non-coding RNAs MEG3, HOTAIR, and MALAT-1 in non-functioning pituitary adenomas and their relationship to tumor behavior. Pituitary, 2015, 18(1), 42-47.
[http://dx.doi.org/10.1007/s11102-014-0554-0] [PMID: 24469926]
[28]
Lu, T.; Yu, C.; Ni, H.; Liang, W.; Yan, H.; Jin, W. Expression of the long non-coding RNA H19 and MALAT-1 in growth hormone-secreting pituitary adenomas and its relationship to tumor behavior. Int. J. Dev. Neurosci., 2018, 67, 46-50.
[http://dx.doi.org/10.1016/j.ijdevneu.2018.03.009] [PMID: 29604339]
[29]
Zhu, Z.; Dai, J.; Liao, Y.; Ma, J.; Zhou, W. Knockdown of long noncoding RNA LINC00152 suppresses cellular proliferation and invasion in glioma cells by regulating miR-4775. Oncol. Res., 2018, 26(6), 857-867.
[http://dx.doi.org/10.3727/096504017X15016337254597] [PMID: 28800786]
[30]
Wu, J.; Shuang, Z.; Zhao, J.; Tang, H.; Liu, P.; Zhang, L.; Xie, X.; Xiao, X. Linc00152 promotes tumorigenesis by regulating DNMTs in triple-negative breast cancer. Biomed. Pharmacother., 2018, 97, 1275-1281.
[http://dx.doi.org/10.1016/j.biopha.2017.11.055] [PMID: 29156515]
[31]
Wang, H.; Chen, W.; Yang, P.; Zhou, J.; Wang, K.; Tao, Q. Knockdown of linc00152 inhibits the progression of gastric cancer by regulating microRNA-193b-3p/ETS1 axis. Cancer Biol. Ther., 2019, 20(4), 461-473.
[http://dx.doi.org/10.1080/15384047.2018.1529124] [PMID: 30404587]
[32]
Zhang, Y.; Xiang, C.; Wang, Y.; Duan, Y.; Liu, C.; Jin, Y.; Zhang, Y. lncRNA LINC00152 knockdown had effects to suppress biological activity of lung cancer via EGFR/PI3K/AKT pathway. Biomed. Pharmacother., 2017, 94, 644-651.
[http://dx.doi.org/10.1016/j.biopha.2017.07.120] [PMID: 28787699]
[33]
Wang, M.; Zhang, R.; Zhang, S.; Xu, R.; Yang, Q. MicroRNA-574-3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells. Gene, 2019, 700, 110-119.
[http://dx.doi.org/10.1016/j.gene.2019.03.043] [PMID: 30917930]
[34]
Cui, K.; Zhang, H.; Wang, G.Z. MiR-483 suppresses cell proliferation and promotes cell apoptosis by targeting SOX3 in breast cancer. Eur. Rev. Med. Pharmacol. Sci., 2019, 23(5), 2069-2074.
[PMID: 30915751]
[35]
Zhuang, X.F.; Zhao, L.X.; Guo, S.P.; Wei, S.; Zhai, J.F.; Zhou, Q.H. miR-34b inhibits the migration/invasion and promotes apoptosis of non-small-cell lung cancer cells by YAF2. Eur. Rev. Med. Pharmacol. Sci., 2019, 23(5), 2038-2046.
[PMID: 30915747]
[36]
Liu, F.; Yin, R.; Chen, X.; Chen, W.; Qian, Y.; Zhao, Y.; Jiang, Y.; Ma, D.; Hu, T.; Yu, T.; Zhu, Y.; Zhang, Y. Over-expression of miR-206 decreases the Euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma. Biomed. Pharmacother., 2019, 114, 108605.
[http://dx.doi.org/10.1016/j.biopha.2019.108605] [PMID: 30904818]
[37]
Wang, Y.; Tai, Q.; Zhang, J.; Kang, J.; Gao, F.; Zhong, F.; Cai, L.; Fang, F.; Gao, Y. MiRNA-206 inhibits hepatocellular carcinoma cell proliferation and migration but promotes apoptosis by modulating cMET expression. Acta Biochim. Biophys. Sin. (Shanghai), 2019, 51(3), 243-253.
[http://dx.doi.org/10.1093/abbs/gmy119] [PMID: 30805592]
[38]
Deng, M.; Qin, Y.; Chen, X.; Wang, Q.; Wang, J. MiR-206 inhibits proliferation, migration, and invasion of gastric cancer cells by targeting the MUC1 gene. OncoTargets Ther., 2019, 12, 849-859.
[http://dx.doi.org/10.2147/OTT.S180021] [PMID: 30774372]
[39]
Sheng, N.; Xu, Y.Z.; Xi, Q.H.; Jiang, H.Y.; Wang, C.Y.; Zhang, Y.; Ye, Q. Overexpression of KIF2A is suppressed by miR-206 and associated with poor prognosis in ovarian cancer. Cell. Physiol. Biochem., 2018, 50(3), 810-822.
[http://dx.doi.org/10.1159/000494467] [PMID: 30352438]

Rights & Permissions Print Cite
Article Metrics
25
2
1
© 2024 Bentham Science Publishers | Privacy Policy